Longer time horizons and therapeutic area expertise make philanthropy venture capital an attractive option for biopharmaceutical companies developing new products. It can also de-risk funding rounds ...

Implementing AI in drug discovery offers significant potential for reducing operating costs, though the extent varies widely.

Job rotations provide an opportunity for promising, high-potential employees to grow and learn new parts of the business.

Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, ...

Carsten Linnemann, Ph.D., CEO of Neogene Therapeutics and Head of Oncology Cell Therapy Clinical Development, AstraZeneca joins Cell & Gene: The Podcast’s Erin Harris to discuss T-cell receptor (TCR) ...

As professionals within the life sciences industry, a new era is upon us, marked by the pursuit of efficiency. In part this has been driven by legislative measures such as the Inflation Reduction Act ...

Cell therapies hold promise for treating malignancies that are currently untreatable. Methods like chimeric antigen receptor (CAR) T cell therapies are being tested in a number of clinical trials, ...

In the second article in a series on the leadership benefits of putting employees first, Christine Miller, president and CEO ...

Examine the pivotal role of comprehensive data analysis solutions in enhancing competitive intelligence within the pharmaceutical industry. As the industry landscape shifts with the rise of generic ...